Company Overview and News
2018-10-16 zacks - 1
Looking for broad exposure to the Large Cap Blend segment of the US equity market? You should consider the First Trust Capital Strength ETF (FTCS - Free Report) , a passively managed exchange traded fund launched on 07/06/2006.
IVV PFZ PGR CTRL CI IVV 500680 PFE PFIZER
(Reuters) - The U.S. government, in an effort to increase pressure on drugmakers to lower costs for U.S. consumers, said on Monday it will propose requiring companies to include the price of their prescription medicines in television ads.
PFZ ABBV 500680 PFE PFIZER ABBV
Last week was not a good one for equities. Even Friday’s partial recovery left behind a loss of 4.2% for the Dow industrials, 4% for the S&P 500, and 3.2% for the Nasdaq Composite. For the year to date, the Dow is up just 2.1%, trailing both the S&P 500 (up 2.6%) and the Nasdaq Composite (up 7%).
PFZ PFIZER V NKE MRK BOE AAPL CSCO MSFT BA 500680 PFE UNH DIS CSCOI
October 11, 2018: Markets opened lower again Thursday and the three major indexes bounced around the break-even line for most of the day before turning solidly lower. Every sector traded lower on the day with energy and financial services posting the biggest dips. About the only good news is that equities may close the day above their intraday lows.
PFZ XOM CVX 500680 PFE PFIZER MCD
Pfizer Inc on Thursday settled charges by New York's attorney general that it misled consumers in its drug copayment coupon program into thinking they would pay far less to fill prescriptions than they ended up having to shell out.
PFZ 500680 PFE PFIZER
NEW YORK (Reuters) - Pfizer Inc on Thursday settled charges by New York’s attorney general that it misled consumers in its drug copayment coupon program into thinking they would pay far less to fill prescriptions than they ended up having to shell out.
PFZ 500680 PFE PFIZER
Pfizer Inc. PFE, -2.68% will pay over $700,000 to settle charges for "deceptive advertising," according to a statement from New York Attorney General Barbara Underwood. Pfizer's stock dropped 2.7% in morning trade, enough to pace the Dow Jones Industrial Average's DJIA, -0.45% decliners. Pfizer's payment includes over $200,000 in restitution for New York consumers and $500,000 in penalties, feels and costs.
PFZ 500680 PFE PFIZER
Myriad Genetics recently signed a commercialization plan with Pfizer Inc. (PFE - Free Report) for FDA approval to use its BRACAnalysis CDx as a companion diagnostic with the latter’s talazoparib. Meanwhile, Thermo Fisher Scientific Inc. (TMO - Free Report) announced the sixth licensing agreement for its B·R·A·H·M·S PCT (procalcitonin) biomarker. In fact, there are many similar developments that clearly point toward the rapid emergence of molecular diagnostics in the MedTech space.
PFZ TMO LMNX MYGN 500680 PFE PFIZER GHDX
Aurobindo Pharma Ltd Thursday said it would be making and marketing azithromycin oral suspension in the US market after getting final approval from the US Food and Drug Administration (USFDA). The oral suspension is to treat mild-to-moderate infections, a press release said here.
PFZ AUROPHARMA 524804 ARBQY 500680 PFE PFIZER
U.S. stocks slumped Wednesday, with major indexes breaching key support levels and extending their downward spiral, as rising bond yields continued to weigh on market sentiment.
SHLD PFZ IMPV TWTR AAPL MYGN SBUX SHLDW MSFT 500680 PFE PFIZER
Shares of Myriad Genetics Inc. MYGN, +7.32% soared 7% Wednesday in a down market, after it announced an agreement to carry out testing for Pfizer Inc. PFE, -0.45% of a treatment for breast cancer. The Salt Lake City, Utah-based company said it will provide BRACAnalysis testing in a mid-stage trial of talazoparib, Pfizer's treatment for "triple negative breast cancer." Myriad specializes in testing hereditary cancers.
PFZ MYGN 500680 PFE PFIZER
Associated Press (AP) recently analyzed and published data regarding brand-name prescription drug prices. This was largely in response to President Donald Trump’s promises during the presidential campaign and in a May policy announcement that he would drive down drug prices. In fact, at the end of May, Trump promised pharma companies would be announcing “massive” voluntary drug prices within two weeks.
MKGAF PFZ MKGAY AYTUZ AYTU 500680 PFE PFIZER
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...